Please assess the completion status of the following clinical trial:

Trial Title: Handling Oxygenation Targets in COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acutely admitted to the ICU AND~* Aged ≥ 18 years AND~* Receives supplemental oxygen with a flow of at least 10 L per minutes in an open system including high-flow systems OR recieves supplemental oxygen in a closed system including invasive or non-invasive ventilation or continuous positive airway pressure (CPAP)-systems AND~* Expected to receive supplemental oxygen for at least 24 hours in the ICU AND~* Having an arterial line for PaO2 monitoring AND~* Confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) in the time leading to or during current hospital admission~Exclusion Criteria:~* Cannot be randomised within twelve hours after present ICU admission~* Chronic mechanical ventilation for any reason~* Use of home oxygen~* Previous treatment with bleomycin~* Organ transplant during current hospital admission~* Withdrawal from active therapy or brain death deemed imminent~* Fertile woman (\< 50 years of age) with positive urine human gonadotropin (hCG) or plasma-hCG~* Carbon monoxide poisoning~* Cyanide poisoning~* Methaemoglobinaemia~* Paraquat poisoning~* Any condition expected to involve the use of hyperbaric oxygen (HBO)~* Sickle cell disease~* Consent not obtainable according to national regulations~* Previously randomised into the HOT-COVID trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low oxygenation target (Type: EXPERIMENTAL): Partial pressure of oxygen in arterial blood (PaO2) 8 kPa (60 mmHg)
- High oxygenation target (Type: ACTIVE_COMPARATOR): Partial pressure of oxygen in arterial blood (PaO2) 12 kPa (90 mmHg)

Based on this trial design, predict the completion outcome and termination type (if applicable).